Cargando…

Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?

The prognosis of patients with advanced melanoma has improved dramatically. However, the clinical outcomes of patients with highly elevated serum lactate dehydrogenase (LDH) remain very poor. The aim of this study was to explore whether patients with normalized LDH after targeted therapy could benef...

Descripción completa

Detalles Bibliográficos
Autores principales: Schouwenburg, Maartje G., Suijkerbuijk, Karijn P.M., Koornstra, Rutger H.T., Jochems, Anouk, van Zeijl, Michiel C.T., van den Eertwegh, Alfons J.M., Haanen, John B.A.G., Aarts, Maureen J.B., van Akkooi, Alexander C.J., van den Berkmortel, Franchette W.P.J., de Groot, Jan Willem B., Hospers, Geke A.P., Kapiteijn, Ellen, Kruit, Wim H., Piersma, Djura, van Rijn, Rozemarijn S., ten Tije, Albert J., Vreugdenhil, Gerard, van der Hoeven, Jacobus J.M., Wouters, Michel W.J.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966631/
https://www.ncbi.nlm.nih.gov/pubmed/31817189
http://dx.doi.org/10.3390/cancers11121940
_version_ 1783488780566528000
author Schouwenburg, Maartje G.
Suijkerbuijk, Karijn P.M.
Koornstra, Rutger H.T.
Jochems, Anouk
van Zeijl, Michiel C.T.
van den Eertwegh, Alfons J.M.
Haanen, John B.A.G.
Aarts, Maureen J.B.
van Akkooi, Alexander C.J.
van den Berkmortel, Franchette W.P.J.
de Groot, Jan Willem B.
Hospers, Geke A.P.
Kapiteijn, Ellen
Kruit, Wim H.
Piersma, Djura
van Rijn, Rozemarijn S.
ten Tije, Albert J.
Vreugdenhil, Gerard
van der Hoeven, Jacobus J.M.
Wouters, Michel W.J.M.
author_facet Schouwenburg, Maartje G.
Suijkerbuijk, Karijn P.M.
Koornstra, Rutger H.T.
Jochems, Anouk
van Zeijl, Michiel C.T.
van den Eertwegh, Alfons J.M.
Haanen, John B.A.G.
Aarts, Maureen J.B.
van Akkooi, Alexander C.J.
van den Berkmortel, Franchette W.P.J.
de Groot, Jan Willem B.
Hospers, Geke A.P.
Kapiteijn, Ellen
Kruit, Wim H.
Piersma, Djura
van Rijn, Rozemarijn S.
ten Tije, Albert J.
Vreugdenhil, Gerard
van der Hoeven, Jacobus J.M.
Wouters, Michel W.J.M.
author_sort Schouwenburg, Maartje G.
collection PubMed
description The prognosis of patients with advanced melanoma has improved dramatically. However, the clinical outcomes of patients with highly elevated serum lactate dehydrogenase (LDH) remain very poor. The aim of this study was to explore whether patients with normalized LDH after targeted therapy could benefit from subsequent treatment with immune checkpoint inhibitors (ICI). Data from all patients with BRAF-mutant metastatic melanoma with a highly elevated serum LDH at baseline (≥2× upper limit of normal) receiving first-line targeted therapy between 2012 and 2019 in the Netherlands were collected. Patients were stratified according to response status to targeted therapy and change in LDH at start of subsequent treatment with ICI. Differences in overall survival (OS) between the subgroups were compared using log-rank tests. After a median follow-up of 35.1 months, median OS of the total study population (n = 360) was 4.9 months (95% CI 4.4–5.4). Of all patients receiving subsequent treatment with ICI (n = 113), survival from start of subsequent treatment was significantly longer in patients who had normalized LDH and were still responding to targeted therapy compared to those with LDH that remained elevated (median OS 24.7 vs. 1.1 months). Our study suggests that introducing ICI upon response to targeted therapy with normalization of LDH could be an effective strategy in obtaining long-term survival in advanced melanoma patients with initial highly elevated serum LDH.
format Online
Article
Text
id pubmed-6966631
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-69666312020-02-04 Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH? Schouwenburg, Maartje G. Suijkerbuijk, Karijn P.M. Koornstra, Rutger H.T. Jochems, Anouk van Zeijl, Michiel C.T. van den Eertwegh, Alfons J.M. Haanen, John B.A.G. Aarts, Maureen J.B. van Akkooi, Alexander C.J. van den Berkmortel, Franchette W.P.J. de Groot, Jan Willem B. Hospers, Geke A.P. Kapiteijn, Ellen Kruit, Wim H. Piersma, Djura van Rijn, Rozemarijn S. ten Tije, Albert J. Vreugdenhil, Gerard van der Hoeven, Jacobus J.M. Wouters, Michel W.J.M. Cancers (Basel) Article The prognosis of patients with advanced melanoma has improved dramatically. However, the clinical outcomes of patients with highly elevated serum lactate dehydrogenase (LDH) remain very poor. The aim of this study was to explore whether patients with normalized LDH after targeted therapy could benefit from subsequent treatment with immune checkpoint inhibitors (ICI). Data from all patients with BRAF-mutant metastatic melanoma with a highly elevated serum LDH at baseline (≥2× upper limit of normal) receiving first-line targeted therapy between 2012 and 2019 in the Netherlands were collected. Patients were stratified according to response status to targeted therapy and change in LDH at start of subsequent treatment with ICI. Differences in overall survival (OS) between the subgroups were compared using log-rank tests. After a median follow-up of 35.1 months, median OS of the total study population (n = 360) was 4.9 months (95% CI 4.4–5.4). Of all patients receiving subsequent treatment with ICI (n = 113), survival from start of subsequent treatment was significantly longer in patients who had normalized LDH and were still responding to targeted therapy compared to those with LDH that remained elevated (median OS 24.7 vs. 1.1 months). Our study suggests that introducing ICI upon response to targeted therapy with normalization of LDH could be an effective strategy in obtaining long-term survival in advanced melanoma patients with initial highly elevated serum LDH. MDPI 2019-12-04 /pmc/articles/PMC6966631/ /pubmed/31817189 http://dx.doi.org/10.3390/cancers11121940 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Schouwenburg, Maartje G.
Suijkerbuijk, Karijn P.M.
Koornstra, Rutger H.T.
Jochems, Anouk
van Zeijl, Michiel C.T.
van den Eertwegh, Alfons J.M.
Haanen, John B.A.G.
Aarts, Maureen J.B.
van Akkooi, Alexander C.J.
van den Berkmortel, Franchette W.P.J.
de Groot, Jan Willem B.
Hospers, Geke A.P.
Kapiteijn, Ellen
Kruit, Wim H.
Piersma, Djura
van Rijn, Rozemarijn S.
ten Tije, Albert J.
Vreugdenhil, Gerard
van der Hoeven, Jacobus J.M.
Wouters, Michel W.J.M.
Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?
title Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?
title_full Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?
title_fullStr Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?
title_full_unstemmed Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?
title_short Switching to Immune Checkpoint Inhibitors upon Response to Targeted Therapy; The Road to Long-Term Survival in Advanced Melanoma Patients with Highly Elevated Serum LDH?
title_sort switching to immune checkpoint inhibitors upon response to targeted therapy; the road to long-term survival in advanced melanoma patients with highly elevated serum ldh?
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6966631/
https://www.ncbi.nlm.nih.gov/pubmed/31817189
http://dx.doi.org/10.3390/cancers11121940
work_keys_str_mv AT schouwenburgmaartjeg switchingtoimmunecheckpointinhibitorsuponresponsetotargetedtherapytheroadtolongtermsurvivalinadvancedmelanomapatientswithhighlyelevatedserumldh
AT suijkerbuijkkarijnpm switchingtoimmunecheckpointinhibitorsuponresponsetotargetedtherapytheroadtolongtermsurvivalinadvancedmelanomapatientswithhighlyelevatedserumldh
AT koornstrarutgerht switchingtoimmunecheckpointinhibitorsuponresponsetotargetedtherapytheroadtolongtermsurvivalinadvancedmelanomapatientswithhighlyelevatedserumldh
AT jochemsanouk switchingtoimmunecheckpointinhibitorsuponresponsetotargetedtherapytheroadtolongtermsurvivalinadvancedmelanomapatientswithhighlyelevatedserumldh
AT vanzeijlmichielct switchingtoimmunecheckpointinhibitorsuponresponsetotargetedtherapytheroadtolongtermsurvivalinadvancedmelanomapatientswithhighlyelevatedserumldh
AT vandeneertweghalfonsjm switchingtoimmunecheckpointinhibitorsuponresponsetotargetedtherapytheroadtolongtermsurvivalinadvancedmelanomapatientswithhighlyelevatedserumldh
AT haanenjohnbag switchingtoimmunecheckpointinhibitorsuponresponsetotargetedtherapytheroadtolongtermsurvivalinadvancedmelanomapatientswithhighlyelevatedserumldh
AT aartsmaureenjb switchingtoimmunecheckpointinhibitorsuponresponsetotargetedtherapytheroadtolongtermsurvivalinadvancedmelanomapatientswithhighlyelevatedserumldh
AT vanakkooialexandercj switchingtoimmunecheckpointinhibitorsuponresponsetotargetedtherapytheroadtolongtermsurvivalinadvancedmelanomapatientswithhighlyelevatedserumldh
AT vandenberkmortelfranchettewpj switchingtoimmunecheckpointinhibitorsuponresponsetotargetedtherapytheroadtolongtermsurvivalinadvancedmelanomapatientswithhighlyelevatedserumldh
AT degrootjanwillemb switchingtoimmunecheckpointinhibitorsuponresponsetotargetedtherapytheroadtolongtermsurvivalinadvancedmelanomapatientswithhighlyelevatedserumldh
AT hospersgekeap switchingtoimmunecheckpointinhibitorsuponresponsetotargetedtherapytheroadtolongtermsurvivalinadvancedmelanomapatientswithhighlyelevatedserumldh
AT kapiteijnellen switchingtoimmunecheckpointinhibitorsuponresponsetotargetedtherapytheroadtolongtermsurvivalinadvancedmelanomapatientswithhighlyelevatedserumldh
AT kruitwimh switchingtoimmunecheckpointinhibitorsuponresponsetotargetedtherapytheroadtolongtermsurvivalinadvancedmelanomapatientswithhighlyelevatedserumldh
AT piersmadjura switchingtoimmunecheckpointinhibitorsuponresponsetotargetedtherapytheroadtolongtermsurvivalinadvancedmelanomapatientswithhighlyelevatedserumldh
AT vanrijnrozemarijns switchingtoimmunecheckpointinhibitorsuponresponsetotargetedtherapytheroadtolongtermsurvivalinadvancedmelanomapatientswithhighlyelevatedserumldh
AT tentijealbertj switchingtoimmunecheckpointinhibitorsuponresponsetotargetedtherapytheroadtolongtermsurvivalinadvancedmelanomapatientswithhighlyelevatedserumldh
AT vreugdenhilgerard switchingtoimmunecheckpointinhibitorsuponresponsetotargetedtherapytheroadtolongtermsurvivalinadvancedmelanomapatientswithhighlyelevatedserumldh
AT vanderhoevenjacobusjm switchingtoimmunecheckpointinhibitorsuponresponsetotargetedtherapytheroadtolongtermsurvivalinadvancedmelanomapatientswithhighlyelevatedserumldh
AT woutersmichelwjm switchingtoimmunecheckpointinhibitorsuponresponsetotargetedtherapytheroadtolongtermsurvivalinadvancedmelanomapatientswithhighlyelevatedserumldh